|
市場調査レポート
商品コード
1321845
標的タンパク質分解の世界市場 (2023-2030年)：用途・技術 (PROTACs・LYTACs)・治療領域・適応症別の規模・シェア・成長分析・予測Global Targeted Protein Degradation Market Size, Share, Growth Analysis, By Application, By Technology(PROTACs, LYTACs ), By Therapeutic area, By Indication - Industry Forecast 2023-2030 |
||||||
|
|
|||||||
| 標的タンパク質分解の世界市場 (2023-2030年)：用途・技術 (PROTACs・LYTACs)・治療領域・適応症別の規模・シェア・成長分析・予測 |
|
出版日: 2023年07月14日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
世界の標的タンパク質分解の市場規模は、2021年の1億331万米ドル、2022年の1億1,385万米ドルから、予測期間中は10.2％のCAGRで推移し、2030年には2億4,761万米ドルの規模に成長すると予測されています。
標的タンパク質分解は、比較的最近の薬剤開発戦略であり、微小な化合物を用いて病気の原因となるタンパク質を特異的に破壊するため、人気が高まっています。この方法は、医薬品開発における従来型のアプローチに比べ、多くの利点をもたらすと言われています。その利点とは、ユニークな作用方法、併用療法の可能性、幅広い適用性、選択性の向上、高い耐久性などです。
多くの疾患に対するより効率的な治療に対する需要の高まりが、標的タンパク質分解市場の推進要因の一つです。患者の健康や生活の質に大きな影響を与えることから、癌、遺伝子異常、自己免疫疾患などの疾患の根本的な原因に対処できる医薬品に対する需要が高まっています。標的タンパク質の分解によって、病気の原因となるタンパク質に優先的に焦点を当てることができれば、副作用の少ない、より効果的な治療法につながる可能性があります。この戦略により、健康な細胞や組織を保護しながら、病原体を引き起こすタンパク質を選択的に攻撃する薬を作り出すことが可能となります。
経口薬開発への注目の高まりは、標的タンパク質分解における市場の主要な発展の一つです。利便性とコンプライアンスに優れた、患者に優しい医薬品へのニーズの高まりが、この開発を後押ししています。経口薬は自宅で便利に摂取でき、治療のために患者が病院やクリニックに出向く必要がないため、注射や点滴のような他のドラッグデリバリーに比べて大きなメリットがあります。いくつかの製薬会社は標的タンパク質を分解する経口薬のR&Dに多額の投資を行っており、消化器系を通過し、体内の標的臓器に到達できる薬剤が開発されています。
当レポートでは、世界の標的タンパク質分解の市場を調査し、市場概要、市場への各種影響因子の分析、技術・イノベーションの動向、法規制環境、市場規模の推移・予測、各種区分・地域別の内訳、競合情勢、主要企業のプロファイルなどをまとめています。
目次
エグゼクティブサマリー
調査手法
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主要市場洞察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料分析
- イノベーションマトリックス
- パイプライン製品の分析
- マクロ経済指標
- 主要投資分析
- 主要成功要因
- 競合の程度
市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制状況
- ポーターの分析
- 将来のディスラプションに関するSkyquestの特別な洞察
世界の標的タンパク質分解市場：用途別
- 市場概要
- 低分子創薬
- タンパク質発見
- 研究
- その他
世界の標的タンパク質分解市場：技術別
- 市場概要
- PROTACs
- LYTACs
- SNIPERs
- 分子接着剤
- その他
世界の標的タンパク質分解市場：治療領域別
- 市場概要
- 腫瘍
- 免疫
- 遺伝性疾患・その他
世界の標的タンパク質分解市場：適応症別
- 市場概要
- 乳癌
- 肺癌
- 白血病
- 固形腫瘍・その他
世界の標的タンパク質分解市場：地域別
- 市場概要
- 北米
- 欧州
- アジア太平洋
- ラテンアメリカ
- 中東・アフリカ
競合情勢
- トップ5社の比較
- 主要企業の市場での位置付け
- 主要企業の採用戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア
主要企業プロファイル
- Arvinas, Inc.
- C4 Therapeutics
- Kymera Therapeutics
- Nurix Therapeutics
- Dewpoint Therapeutics
- PROTACs Therapeutics
- Amgen Inc.
- AstraZeneca
- Bayer AG
- Celgene Corporation
- Genentech, Inc.
- Gilead Sciences, Inc.
- Novartis AG
- Sanofi SA
- Takeda Pharmaceutical Company Limited.
Global Targeted Protein Degradation Market size was valued at USD 103.31 million in 2021 and is poised to grow from USD 113.85 million in 2022 to USD 247.61 million by 2030, growing at a CAGR of 10.2% in the forecast period (2023-2030).
Since it is a relatively recent strategy for medication development and uses tiny compounds to specifically destroy disease-causing proteins, targeted protein degradation is growing in popularity. This method is said to provide a number of benefits over more conventional approaches to drug development. These benefits include unique method of action, potential for combination therapy, broad applicability, improved selectivity, and higher durability. Top-down and bottom-up approaches were used to estimate and validate the size of Targeted Protein Degradation and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Segments covered in this report:
Applications, technologies, therapeutic areas, indications, and geographical regions are used to segment the global market for targeted protein degradation. The market is divided into Small Molecule Drug Discovery, Protein Discovery, Research Applications, and Other End Use Applications. The market has been divided into PROTACs (Proteolysis-Targeting Chimeras), LYTACs (Lysosome-Targeting Chimeras), SNIPERs (Specific and Non-genetic IAP-dependent Protein ERasers), molecular glues, and other categories based on technology. The market is divided into oncology, immunology, genetic disorders, and other diseases based on therapeutic area. According to preliminary data, the market is divided into categories for solid tumors, leukemia, breast cancer, and lung cancer. North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America are the different geographic segments of the market.
Driver
Increasing Demand for Effective Cancer Treatment to Boost Market Growth
The growing demand for more efficient treatments for a number of disorders is one of the reasons propelling the market for targeted protein degradation. There is a rising demand for medicines that can address the underlying causes of diseases like cancer, genetic abnormalities, and autoimmune diseases because they have a substantial influence on patients' health and quality of life. The potential for preferentially focusing on disease-causing proteins through targeted protein breakdown could lead to more effective treatments with fewer adverse effects. This strategy makes it possible to create medications that selectively attack the pathogen-causing proteins while protecting healthy cells and tissues.
Restraints
Complexity of Targeted Protein Degradation to Hinder Market Growth
The complexity of this industry is one of the main obstacles facing the targeted protein degradation market. This strategy necessitates a thorough knowledge of the structure and purpose of proteins in addition to sophisticated skills in drug research and design. This technique can make it difficult and time-consuming to develop novel therapeutics, which could impede the field's advancement. Developing medications that can selectively degrade particular proteins within cells is a relatively new and complicated field known as targeted protein degradation. These medications are made to benefit from the cell's built-in machinery for protein breakdown, which enables them to specifically target disease-causing proteins while sparing healthy cells.
Market Trend
The increased focus on oral medication development is one of the market's major developments in targeted protein degradation. The rising need for more patient-friendly medicines that provide better convenience and compliance is what is driving this development. Because they may be conveniently administered at home and don't require patients to travel to hospitals or clinics for treatment, oral medications offer a substantial benefit over other drug delivery methods like injections and infusions. Several pharmaceutical companies are making significant investments in the research and development of oral medications for targeted protein breakdown to counter this tendency. Drugs that can make it past the digestive system and into the body's target organs are being developed.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Targeted Protein Degradation Market by Application
- Market Overview
- Small Molecule drug discovery
- protein discovery
- research applications
- and others
Global Targeted Protein Degradation Market by Technology
- Market Overview
- PROTACs (Proteolysis-Targeting Chimeras)
- LYTACs (Lysosome-Targeting Chimeras)
- and SNIPERs (Specific and Non-genetic IAP-dependent Protein ERasers)
- Molecular glues
- and others
Global Targeted Protein Degradation Market by Therapeutic area
- Market Overview
- Oncology
- immunology
- genetic disorder and other diseases
Global Targeted Protein Degradation Market by Indication
- Market Overview
- Breast cancer
- lung cancer
- leukemia
- solid tumors and others
Global Targeted Protein Degradation Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Arvinas, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- C4 Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Kymera Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Nurix Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dewpoint Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PROTACs Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Celgene Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Genentech, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gilead Sciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
